$4.81
1.69%
Nasdaq, Oct 05, 04:00 pm EDT. Closed.
ISIN
US0926671043
Symbol
SRTA

Strata Critical Medical Target price 2026 - Analyst rating & recommendation

Strata Critical Medical Classifications & Recommendation

Buy
90%
Hold
10%

Strata Critical Medical Price Target

Target Price $8.93
Price $4.81
Potential
Number of Estimates 6
6 Analysts have issued a price target Strata Critical Medical 2027 . The average Strata Critical Medical target price is $8.93. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend Strata Critical Medical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Strata Critical Medical stock has an average upside potential 2027 of . Most analysts recommend the Strata Critical Medical stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 197.14 296.62
20.73% 50.46%
EBITDA Margin -10.02% 11.46%
12.18% 214.39%
Net Margin 20.97% -1.83%
291.00% 108.72%

6 Analysts have issued a sales forecast Strata Critical Medical 2026 . The average Strata Critical Medical sales estimate is

$297m
unlock
. This is
15.88% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$307m 19.98%
unlock
, the lowest is
$283m 10.68%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $197m 20.73%
2026
$297m 50.46%
unlock
2027
$333m 12.14%
unlock

6 Analysts have issued an Strata Critical Medical EBITDA forecast 2026. The average Strata Critical Medical EBITDA estimate is

$34.0m
unlock
. This is
450.92% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$35.5m 466.25%
unlock
, the lowest is
$32.4m 434.76%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-19.8m 11.08%
2026
$34.0m 272.17%
unlock
2027
$41.7m 22.49%
unlock

EBITDA Margin

2025 -10.02% 12.18%
2026
11.46% 214.39%
unlock
2027
12.52% 9.25%
unlock

6 Strata Critical Medical Analysts have issued a net profit forecast 2026. The average Strata Critical Medical net profit estimate is

$-5.4m
unlock
. This is
113.45% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-4.6m 111.54%
unlock
, the lowest is
$-6.1m 115.09%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $41.4m 251.41%
2026
$-5.4m 113.08%
unlock
2027
$6.8m 225.14%
unlock

Net Margin

2025 20.97% 291.00%
2026
-1.83% 108.72%
unlock
2027
2.03% 210.93%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ 0.50 -0.06
242.86% 112.00%
P/E negative
EV/Sales 1.33

6 Analysts have issued a Strata Critical Medical forecast for earnings per share. The average Strata Critical Medical EPS is

$-0.06
unlock
. This is
113.04% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.05 110.87%
unlock
, the lowest is
$-0.07 115.22%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $0.50 242.86%
2026
$-0.06 112.00%
unlock
2027
$0.08 233.33%
unlock

P/E ratio

Current 10.28 145.66%
2026
-77.29 851.66%
unlock
2027
61.83 180.00%
unlock

Based on analysts' sales estimates for 2026, the Strata Critical Medical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.55 1.97%
2026
1.33 13.94%
unlock
2027
1.19 10.82%
unlock

P/S ratio

Current 1.63 20.10%
2026
1.41 13.70%
unlock
2027
1.26 10.82%
unlock

Current Strata Critical Medical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B. Riley Securities
Locked
➜
Locked
Locked Mar 25 2026
Craig-Hallum
Locked
➜
Locked
Locked Mar 25 2026
Lake Street
Locked
➜
Locked
Locked Feb 26 2025
JP Morgan
Locked
➜
Locked
Locked Oct 29 2024
Analyst Rating Date
Locked
B. Riley Securities:
Locked
➜
Locked
Mar 25 2026
Locked
Craig-Hallum:
Locked
➜
Locked
Mar 25 2026
Locked
Lake Street:
Locked
➜
Locked
Feb 26 2025
Locked
JP Morgan:
Locked
➜
Locked
Oct 29 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today